within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08C_SelectiveCalciumChannelBlockersWithMainlyVascula.C08CA15_Benidipine;

model Benidipine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.06,
    Cl = 0.0001263888888888889,
    adminDuration = 600,
    adminMass = 8 / 1000000,
    adminCount = 1,
    Vd = 0.0066,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004833333333333333,
    Tlag = 19.8,
    Vdp = 0.0040999999999999995,
    k12 = 0.0001186111111111111,
    k21 = 0.0001186111111111111);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Benidipine</td></tr><tr><td>ATC code:</td><td>C08CA15</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.5</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Benidipine is a dihydropyridine calcium channel blocker used for the treatment of hypertension and angina pectoris. It is an approved oral antihypertensive agent in several Asian countries, including Japan, but is not approved in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult Japanese volunteers after a single oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C08CA15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Benidipine;
